An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A (Q22000603)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A |
scientific article |
Statements
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A (English)
0 references
Walter Gilbert
Walter
Gilbert
1 reference
1 reference
1 reference
1 reference
1 reference
Shahram Attarian
1 reference
Jean-Michel Vallat
1 reference
Benoît Funalot
1 reference
Pierre-Marie Gonnaud
1 reference
Odile Dubourg
1 reference
Jean Pouget
1 reference
Joëlle Micallef
1 reference
Jérôme Franques
1 reference
Marie-Noëlle Lefebvre
1 reference
Karima Ghorab
1 reference
Mahmoud Al-Moussawi
1 reference
Vincent Tiffreau
1 reference
Marguerite Preudhomme
1 reference
Armelle Magot
1 reference
Laurène Leclair-Visonneau
1 reference
Tanya Stojkovic
1 reference
Laura Bossi
1 reference
Philippe Lehert
1 reference
Viviane Bertrand
1 reference
Jonas Mandel
1 reference
Aude Milet
1 reference
Rodolphe Hajj
1 reference
Lamia Boudiaf
1 reference
Catherine Scart-Grès
1 reference
Serguei Nabirotchkin
1 reference
Mickael Guedj
1 reference
Ilya Chumakov
1 reference
2014
0 references
9
0 references
1
0 references
199
0 references
1 December 2014
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference